ASND — Recent News Coverage

All news mentioning ASND in ESEN's AI-graded feed

News stories with ASND as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on ASND. See /coverage/ASND for the 30-day aggregate.

5 articles Updated: 2026-09-12 12:06 UTC Filter: Ticker: $ASND
SEEKINGALPHA.COM · 2026-08-13 LOW NEUTRAL CORR0.12

Ascendis Pharma A/S (ASND) Q2 2026 Earnings Call Transcript

$ASND
◈ ESEN AI
This article represents a scheduled earnings call transcript for Ascendis Pharma (ASND), classified as a procedural disclosure rather than a market-moving catalyst. The company conducted its Q2 2026 earnings presentatio…
MANILATIMES.NET · 2026-08-13 LOW BULLISH CORR0.42

Ascendis Pharma Reports Second Quarter 2026 Financial Results

$ASND
◈ ESEN AI
Ascendis Pharma reported Q2 2026 results showing robust revenue momentum, with product sales reaching €315 million, nearly doubling year-over-year. The growth was driven by three commercial products: YORVIPATH® (€252M),…
MANILATIMES.NET · 2026-06-26 NEUTRAL BULLISH CORR0.42

Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®

$ASND
◈ ESEN AI
Ascendis Pharma (ASND) has been added to multiple Russell index families including the Russell 3000, Russell 1000, Russell 2500, and Russell Midcap as part of the semi-annual 2026 reconstitution. This multi-index inclus…
SEEKINGALPHA.COM · 2026-06-15 LOW NEUTRAL CORR0.15

Ascendis Pharma A/S (ASND) Presents at Endocrine Society's Annual Meeting (ENDO 2026) - Slideshow (NASDAQ:ASND) 2026-06-15

$ASND
◈ ESEN AI
Ascendis Pharma (ASND) presented scientific data at the Endocrine Society's annual meeting, a routine conference appearance typical for biopharmaceutical companies seeking to disseminate clinical research and build inve…
MANILATIMES.NET · 2026-06-11 NEUTRAL BULLISH CORR0.42

5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism

$ASND
◈ ESEN AI
Ascendis Pharma (ASND) released Phase 2 five-year efficacy data for TransCon PTH, demonstrating sustained systemic benefits in hypoparathyroidism treatment. The extended dataset validates multi-organ system responses al…
EXPLORE OTHER FILTERS